Once-Weekly Semaglutide in Adults with Overweight or Obesity

20214,043 citationsJournal Article

Authors

John Wilding · University of Liverpool

Rachel L. Batterham · University College Hospital

Salvatore Calanna · Novo Nordisk (Denmark)

Melanie J. Davies · University of Leicester

Luc F. Van Gaal · University of Antwerp

Ildiko Lingvay · National Institute for Health Research

Barbara McGowan

Abstract

In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight. (Funded by Novo Nordisk; STEP 1 ClinicalTrials.gov number, NCT03548935).

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Pharmacology and Obesity Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 384, Issue 11, pp. 989-1002

DOI: 10.1056/nejmoa2032183

Field-Weighted Citation Impact: 341.94